Total Payments
$86,427
2024 Payments
$24,610
Companies
10
Transactions
97
Payment Breakdown by Category
Consulting$62,721 (72.6%)
Other$11,649 (13.5%)
Research$6,149 (7.1%)
Travel$4,290 (5.0%)
Food & Beverage$1,618 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $62,721 | 32 | 72.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,649 | 7 | 11.2% |
| Unspecified | $6,149 | 13 | 7.1% |
| Travel and Lodging | $4,290 | 21 | 5.0% |
| Honoraria | $2,000 | 1 | 2.3% |
| Food and Beverage | $1,618 | 23 | 1.9% |
Payments by Type
General
$80,278
84 transactions
Research
$6,149
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | $27,444 | 14 | $0 (2024) |
| GENZYME CORPORATION | $26,948 | 47 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $12,991 | 14 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,721 | 14 | $0 (2023) |
| Chiesi USA, Inc. | $5,335 | 3 | $0 (2022) |
| Amicus Therapeutics, Inc. | $2,973 | 1 | $0 (2019) |
| PFIZER INC. | $1,878 | 1 | $0 (2018) |
| Spark Therapeutics, Inc. | $700.00 | 1 | $0 (2021) |
| BIOVERATIV THERAPEUTICS INC. | $420.00 | 1 | $0 (2020) |
| SANOFI PASTEUR INC. | $16.58 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,610 | 8 | BioMarin Pharmaceutical Inc. ($20,770) |
| 2023 | $3,960 | 4 | GENZYME CORPORATION ($3,198) |
| 2022 | $4,431 | 2 | BioMarin Pharmaceutical Inc. ($2,976) |
| 2021 | $8,757 | 5 | GENZYME CORPORATION ($4,160) |
| 2020 | $14,224 | 17 | Takeda Pharmaceuticals U.S.A., Inc. ($7,451) |
| 2019 | $17,283 | 32 | GENZYME CORPORATION ($8,193) |
| 2018 | $1,878 | 1 | PFIZER INC. ($1,878) |
| 2017 | $11,284 | 28 | GENZYME CORPORATION ($5,904) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $3,840.00 | General |
| Category: Genetic Disease | ||||||
| 12/31/2023 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $491.78 | General |
| 09/28/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,948.00 | General |
| 07/31/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: Fabry Disease Registry Protocol • Category: Genetic Disease | ||||||
| 07/05/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $270.00 | General |
| 10/31/2022 | BioMarin Pharmaceutical Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,976.00 | General |
| 08/18/2022 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| 12/17/2021 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 06/28/2021 | Spark Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 06/17/2021 | SANOFI PASTEUR INC. | VAXELIS (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Vaccines | ||||||
| 05/04/2021 | GENZYME CORPORATION | FABRAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $4,160.00 | General |
| Category: Genetic Disease | ||||||
| 01/12/2021 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $2,425.00 | General |
| Category: HEMATOLOGY, DISEASE | ||||||
| 12/15/2020 | GENZYME CORPORATION | FABRAZYME (Biological) | — | In-kind items and services | $983.08 | Research |
| Study: Fabry Disease Registry & Pregnancy Sub-registry • Category: Genetic Disease | ||||||
| 11/04/2020 | Alexion Pharmaceuticals, Inc. | Strensiq (Drug) | Consulting Fee | Cash or cash equivalent | $4,700.00 | General |
| Category: Endocrinology | ||||||
| 03/31/2020 | GENZYME CORPORATION | FABRAZYME (Biological) | — | In-kind items and services | $670.00 | Research |
| Study: FABRY REGISTRY • Category: Genetic Disease | ||||||
| 03/16/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,780.00 | General |
| 03/13/2020 | BIOVERATIV THERAPEUTICS INC. | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| 03/04/2020 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Consulting Fee | Cash or cash equivalent | $2,580.00 | General |
| Category: GENETIC DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Lysosomal Acid Lipase LAL Deficiency Registry ALX-LALD-501 | Alexion Pharmaceuticals, Inc. | $1,805 | 4 |
| Fabry Disease Registry Protocol | GENZYME CORPORATION | $1,250 | 1 |
| Fabry Disease Registry & Pregnancy Sub-registry | GENZYME CORPORATION | $983.08 | 1 |
| Fabry Disease Registry | GENZYME CORPORATION | $734.41 | 4 |
| Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-na?ve Adult Male Patients With Fabry Disease | GENZYME CORPORATION | $706.16 | 2 |
| FABRY REGISTRY | GENZYME CORPORATION | $670.00 | 1 |
About William Wilcox
William Wilcox is a Clinical Genetics (M.D.) healthcare provider based in Decatur, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205896933.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, William Wilcox has received a total of $86,427 in payments from pharmaceutical and medical device companies, with $24,610 received in 2024. These payments were reported across 97 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($62,721).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Location Decatur, GA
- Active Since 03/25/2006
- Last Updated 09/23/2019
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1205896933
Products in Payments
- FABRAZYME (Drug) $12,529
- Strensiq (Drug) $11,186
- FABRAZYME (Biological) $10,903
- FERRIPROX (Drug) $3,880
- VPRIV (Biological) $3,671
- GZ402671 (Drug) $1,000
- NO PRODUCT DISCUSSED (Drug) $567.90
- VAXELIS (Biological) $16.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Genetics (M.D.) Doctors in Decatur
Hong Li, M.d.,Ph.d, M.D.,PH.D
Clinical Genetics (M.D.) — Payments: $18,196
Clinical Genetics (M.D.) $18,196
Dr. Michael Gambello, Md, Phd, MD, PHD
Clinical Genetics (M.D.) — Payments: $8,764
Clinical Genetics (M.D.) $8,764
Dr. Daniel Gruskin, M.d, M.D
Clinical Genetics (M.D.) — Payments: $15.56
Clinical Genetics (M.D.) $15.56
Dr. Richard Olney
Clinical Genetics (M.D.)
Clinical Genetics (M.D.)